Merck & Co. Inc. (MRK) has unveiled positive results from a Phase 2b/3 trial evaluating clesrovimab, a monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease. The trial met all primary endpoints, demonstrating a significant reduction in RSV-associated infections and hospitalizations. Interim results from an ongoing Phase 3 trial also show promising safety and efficacy data, suggesting clesrovimab could be a valuable tool in preventing severe RSV disease in infants.